A cancer nanotherapeutic has been developed that targets the extracellular matrix (ECM)-modifying enzyme lysyl oxidase (LOX) and alters the ECM structure. Poly(d,l-lactide-co-glycolide) nanoparticles (∼220 nm) coated with a LOX inhibitory antibody bind to ECM and suppress mammary cancer cell growth and invasion in vitro as well as tumor expansion in vivo, with greater efficiency than soluble anti-LOX antibody. This nanomaterials approach opens a new path for treating cancer with higher efficacy and decreased side effects.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1021/nl301206p | DOI Listing |
Publication Analysis
Top Keywords
extracellular matrix
8
inhibition mammary
4
mammary tumor
4
tumor growth
4
growth lysyl
4
lysyl oxidase-targeting
4
oxidase-targeting nanoparticles
4
nanoparticles modify
4
modify extracellular
4
matrix cancer
4
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!